USANA Q2 net sales $238M (-10% YoY), EPS $0.89; FY2023 guidance raised at low end

USANA HEALTH SCIENCES INC

2023-Q2 EPS reported $1.84 revenue$486,562,000

Q2 net sales $238M, down 10% YoY; diluted EPS $0.89 vs $1.00.
Active customers 487k, down 13% YoY; sequential rise in mainland China customers (+5%).
FY2023 guidance: net sales $900-950M (prev $875-950M), EPS $2.65-3.30 (prev $2.40-3.30).
Greater China net sales $129M, +4% sequential; mainland China local-currency sales +10% QoQ.
Plans to open 25th market, India, in late 2023; first new market since 2018.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $900 to $950 million, EPS $2.65 to $3.30. Guidance raised.

Period: fiscal year 2023
Revenue: $900 to $950 million
EPS: $2.65 to $3.30
Guidance: raised
Result: guidance update

Exact text from the filing

Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

USANA HEALTH SCIENCES INC reported second quarter ended July 1, 2023 results: revenue $238 million, EPS $0.89.

Period: second quarter ended July 1, 2023
Revenue: $238 million
EPS: $0.89
Result: reported results

Exact text from the filing

Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

USANA HEALTH SCIENCES INC filing history →

Source: SEC EDGAR

accession 0001157523-23-001145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.